OMIA Have an Exciting Year – 2000

27th April 2009

Oxford University and Sir Martin and Lady Wood provided seed funding for Oxford Medical Image Analysis - OMIA - in December 1999. With this investment the business developed rapidly in 2000.

We are now pleased to announce that OMIA and Oxford University Innovation have entered into licence agreements for separate developments by Professor Mike Brady and Dr Alison Noble of the University’s Medical Vision Laboratory on the processing of medical image data. This and previous work provides support for OMIA’s current and future product developments.

OMIA’s first product, Ridgex®, is being integrated into the tumour diagnosis and treatment systems of three leading manufacturers of imaging and of radiotherapy equipment. Ridgex® is expected to go into clinical use during the first half of 2001, following clinical trials and then be made available under a quality system compliant with ISO 9001. Ridgex® attracted great interest at the meeting of the Radiological Society of North America in Chicago in December 2000.

Quamus®, OMIA’s system for analysing and quantifying ultrasound images of the heart, moved into second stage clinical trials in March 2000. A new screen interface, with comprehensive facilities to present the quantification of the echocardiograms, has been well received by clinicians. The American Heart Association meeting in November 2000 once again confirmed that cardiologists want to use echocardiograms to quantify heart function. As a result, all the main echocardiograph equipment manufacturers are showing strong interest in Quamus®.

The next version of Quamus®, which is due to go to our clinical trial clinicians in March 2001, will offer substantially enhanced capabilities. The development of Quamus® is supported both by the European Commission and by the DTI under the SMART award programme.

Having applied for a patent over the summer of 2000, OMIA developed a prototype of its e-Mage™ system. This enables the exchange and comparison of image analysis data over the Internet. This will be used first in the Quamus® clinical trials.

OMIA is currently in active negotiation in relation to the next round of funding.

Press release sign up